UAWJ248
UAWJ248 is a SARS-CoV-2 main protease (Mpro) inhibitor with an IC50 of 0.012 μM. UAWJ248 inhibits activity via initial reversible binding followed by irreversible inactivation. UAWJ248 inhibits SARS-CoV-2 replication and can be used for the research of SARS-CoV-2 infection.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2589736-94-5
- 分子式: C31H45N5O7
- 分子量:599.72
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Vero C1008 | EC50 |
11.1 μM
Compound: 62; UAWJ248
|
Antiviral activity against SARS-CoV-2 USA-WA1/2020 infected in Vero E6 cells assessed as reduction in viral replication incubated for 3 days by viral plaque assay
Antiviral activity against SARS-CoV-2 USA-WA1/2020 infected in Vero E6 cells assessed as reduction in viral replication incubated for 3 days by viral plaque assay
|
[PMID: 37244162] |
体外実験
UAWJ248 potently inhibits tag-free native SARS-CoV-2 Mpro with an IC50 of 0.012 µM and shows IC50 >20 μM for PLpro[1].
UAWJ248 (0.01-100 µM; 48 h) inhibits SARS-CoV-2 replication in Vero E6 cells with an EC50 of 20.49 µM[1].
UAWJ248 (0.01-100 µM) inhibits SARS-CoV-2 replication in Vero E6 cells with an EC50 of 11.1 µM in the plaque assay[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Vero E6 cells
-
Concentration:100 µM, 33 µM, 11 µM, 3.7 µM, 1.1 µM
-
Incubation Time:48 h post-infection
-
Result:Inhibited SARS-CoV-2 replication in a dose-dependent manner, with an EC50 of 20.49 µM.
化学情報
-
CAS 番号 2589736-94-5
-
分子量 599.72
-
分子式 C31H45N5O7
-
SMILES
O=C(NCC1)[C@@H]1C[C@@H](C(C(NC2CC2)=O)=O)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC(OCC3=CC=CC=C3)=O)=O)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)